Clinical Trials
8 trialsNCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02684162 2025-11-06
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01696032 2024-08-27
SGI-110
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT01752933 2024-08-27
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT03603964 2024-08-27
Guadecitabine Extension Study
Astex Pharmaceuticals, Inc.
Phase 2 Terminated
NCT02901899 2024-02-20
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Northwestern University
Phase 2 Completed
NCT03913455 2023-12-20
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT03075826 2022-05-05
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
Weill Medical College of Cornell University
Phase 2 Completed